The Motley Fool Investing Philosophy: We generally recommend investors buy shares of at least 25 stocks and hold them for at least 5 years. Learn More
| 1 Year | 5 Year | 5 Year Annualized | Since IPO | |
|---|---|---|---|---|
| URGN | +102.75% | +4.02% | +0.79% | +42% |
| S&P | +17.78% | +74.31% | +11.75% | +184% |
UroGen Pharma Ltd. is a biopharmaceutical company, which engages in developing and commercializing innovative solutions that treat urothelial and specialty cancers. It also focuses on developing RTGel reverse-thermal hydrogel, a proprietary sustained release and hydrogel-based platform technology. The company was founded by Asher Holzer in 2004 and is headquartered in Princeton, NJ.
A full exit after a monster rally says less about the company’s science and more about how disciplined funds lock in wins when portfolio math starts to matter.
| Q4 2025 | YOY Change | |
|---|---|---|
| Revenue | $37.84M | 54.0% |
| Gross Profit | $34.55M | 56.4% |
| Gross Margin | 91.31% | 1.4% |
| Market Cap | $1.10B | 143.9% |
| Market Cap / Employee | $3.77M | 0.0% |
| Employees | 291 | 23.8% |
| Net Income | -$26,364.00K | 29.7% |
| EBITDA | -$18,436.00K | 32.6% |
Currently no data to display
Currently no data to display.
Currently no data to display.
| Q4 2025 | YOY Change | |
|---|---|---|
| Net Cash | $112.10M | -35.2% |
| Accounts Receivable | $33.08M | 62.9% |
| Inventory | 16.5 | 78.4% |
| Q4 2025 | YOY Change | |
|---|---|---|
| Long Term Debt | $128.33M | 4.0% |
| Short Term Debt | $1.76M | 14.7% |
| Q4 2025 | YOY Change | |
|---|---|---|
| Return On Assets | -63.14% | -8.5% |
| Return On Invested Capital | -584.70% | -10.6% |
| Q4 2025 | YOY Change | |
|---|---|---|
| Free Cash Flow | -$42,529.35K | -202.8% |
| Operating Free Cash Flow | -$42,507.24K | -205.1% |
| Metric | Q1 2025 | Q2 2025 | Q3 2025 | Q4 2025 | YoY Change |
|---|---|---|---|---|---|
| Price to Book | -53.06 | -13.59 | -9.87 | -9.49 | -153.91% |
| Price to Sales | 5.71 | 6.94 | 9.93 | 10.31 | 86.15% |
| Price to Tangible Book Value | -53.06 | -13.60 | -9.87 | -9.49 | -153.91% |
| Enterprise Value to EBITDA | -12.46 | -15.26 | -35.90 | -61.87 | 336.12% |
| Total Debt | $126.36M | $127.47M | $129.94M | $130.09M | 4.14% |
No podcast episodes available.
Invest better with The Motley Fool. Get stock recommendations, portfolio guidance, and more from The Motley Fool's premium services.
